Compare Vistra Corp (VST) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vistra Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Vistra Corp trades at $161.13 (market cap $52.41B), while State Street SPDR S&P Biotech ETF trades at $153.85 (market cap $10.11B). The key difference: Vistra Corp is far larger — about 5.2× State Street SPDR S&P Biotech ETF's market cap, and Vistra Corp pays a 0.59% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vistra Corp for 32 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| VST | XBI | |
|---|---|---|
Market Cap | $52.41B | $10.11B |
Volume | 11,278,074 | 12,903,266 |
Sector | Utilities | Broad Market / Factor |
52-Week High | $210.85 | $169.55 |
52-Week Low | $134.71 | $104.99 |
Typical Hold Time | 32 Days | 38 Days |
Enterprise Value | $74.34B | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vistra Corp. (VST) trades at $161.48, down 3.14% on the day, amid mixed earnings history but strong analyst support. Technicals are bullish with support at $152 and resistance at $164, while fundamentals show robust profitability with an 11.55% net margin and 75.73% ROE. Recent developments include a $4.2 billion US loan for nuclear expansion and a 20-year power deal with New Era Energy, positioning Vistra to capitalize on AI-driven electricity demand.
The outlook is positive with a consensus price target of $215.23 implying 33% upside, driven by nuclear scale and data center partnerships. Risks include earnings volatility and high debt, but institutional bullishness and AI power scarcity trends offer a compelling growth narrative for investors seeking exposure to the energy transition.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
